Vestmark Advisory Solutions’s iShares US Medical Devices ETF IHI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-4,286
Closed -$212K – 1708
2026
Q2
$212K Sell
4,286
-603
-12% -$30.6K ﹤0.01% 1408
2026
Q1
$261K Buy
+4,889
New +$287K ﹤0.01% 1212
2022
Q3
– Sell
-4,090
Closed -$206K – 845
2022
Q2
$206K Sell
4,090
-634
-13% -$34.6K 0.01% 805
2022
Q1
$288K Sell
4,724
-516
-10% -$30.8K 0.02% 726
2021
Q4
$345K Buy
5,240
+445
+9% +$28.5K 0.02% 661
2021
Q3
$301K Buy
4,795
+619
+15% +$39.5K 0.02% 664
2021
Q2
$251K Sell
4,176
-1,506
-27% -$87.1K 0.02% 679
2021
Q1
$313K Buy
5,682
+684
+14% +$37.9K 0.03% 580
2020
Q4
$273K Buy
+4,998
New +$261K 0.03% 499
2020
Q3
– Sell
-5,760
Closed -$254K – 565
2020
Q2
$254K Buy
+5,760
New +$246K 0.04% 451
2019
Q3
– Sell
-9,486
Closed -$381K – 568
2019
Q2
$381K Sell
9,486
-396
-4% -$15K 0.07% 343
2019
Q1
$381K Buy
+9,882
New +$359K 0.07% 335

Other funds holding IHI

Vestmark Advisory Solutions's IHI Position: Q3 2026 in Review

Vestmark Advisory Solutions sold out of iShares US Medical Devices ETF (IHI) in Q3 2026, closing a stake of 4,286 shares — an estimated $212K sold.

Vestmark Advisory Solutions first reported a position in IHI in Q1 2019 and held it in 12 quarters. The position peaked at $381K in Q2 2019. 535 funds tracked by Wall St. Rank hold IHI as of Q3 2026.

  • Vestmark Advisory Solutions reported no remaining iShares US Medical Devices ETF position as of Q3 2026 after selling out during the quarter.
  • Vestmark Advisory Solutions sold 4,286 iShares US Medical Devices ETF shares in Q3 2026, an estimated $212K.
  • Vestmark Advisory Solutions first reported a position in iShares US Medical Devices ETF in Q1 2019 and held it in 12 quarters.
  • Vestmark Advisory Solutions's iShares US Medical Devices ETF position peaked at $381K in Q2 2019.
  • 535 funds tracked by Wall St. Rank held iShares US Medical Devices ETF as of Q3 2026.

Based on Vestmark Advisory Solutions's 13F filing for Q3 2026, filed 16 Nov 2026.